AJP - Endo Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 289: E829-E838, 2005. First published June 7, 2005; doi:10.1152/ajpendo.00165.2005
0193-1849/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/5/E829    most recent
00165.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grefhorst, A.
Right arrow Articles by Kuipers, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grefhorst, A.
Right arrow Articles by Kuipers, F.

Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice

Aldo Grefhorst,1 Theo H. van Dijk,1 Anke Hammer,1 Fjodor H. van der Sluijs,1 Rick Havinga,1 Louis M. Havekes,2 Johannes A. Romijn,3 Pieter H. Groot,4 Dirk-Jan Reijngoud,1 and Folkert Kuipers1

1Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics, University Medical Center Groningen, Groningen; 2TNO Prevention and Health and Departments of General Internal Medicine and Cardiology and of 3Endocrinology and Diabetes, Leiden University Medical Center, Leiden, The Netherlands and the 4Atherosclerosis Department, GlaxoSmithKline Pharmaceuticals, Stevenage, United Kingdom

Submitted 14 April 2005 ; accepted in final form 27 May 2005

Liver X receptor (LXR) agonists have been proposed to act as anti-diabetic drugs. However, pharmacological LXR activation leads to severe hepatic steatosis, a condition usually associated with insulin resistance and type 2 diabetes mellitus. To address this apparent contradiction, lean and ob/ob mice were treated with the LXR agonist GW-3965 for 10 days. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp studies. Hepatic glucose production (HGP) and metabolic clearance rate (MCR) of glucose were determined with stable isotope techniques. Blood glucose and hepatic and whole body insulin sensitivity remained unaffected upon treatment in lean mice, despite increased hepatic triglyceride contents (61.7 ± 7.2 vs. 12.1 ± 2.0 nmol/mg liver, P < 0.05). In ob/ob mice, LXR activation resulted in lower blood glucose levels and significantly improved whole body insulin sensitivity. GW-3965 treatment did not affect HGP under normo- and hyperinsulinemic conditions, despite increased hepatic triglyceride contents (221 ± 13 vs. 176 ± 19 nmol/mg liver, P < 0.05). Clamped MCR increased upon GW-3965 treatment (18.2 ± 1.0 vs. 14.3 ± 1.4 ml·kg–1·min–1, P = 0.05). LXR activation increased white adipose tissue mRNA levels of Glut4, Acc1 and Fasin ob/ob mice only. In conclusion, LXR-induced blood glucose lowering in ob/ob mice was attributable to increased peripheral glucose uptake and metabolism, physiologically reflected in a slightly improved insulin sensitivity. Remarkably, steatosis associated with LXR activation did not affect hepatic insulin sensitivity.

hepatic glucose production; hepatic steatosis; hyperinsulinemic euglycemic clamp; stable isotopes; triglycerides



Address for reprint requests and other correspondence: A. Grefhorst, Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics, Rm. Y2117, CMC IV, Univ. Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands (e-mail: A.Grefhorst{at}med.umcg.nl)




This article has been cited by other articles:


Home page
J EndocrinolHome page
C. J Delvecchio and J. P Capone
Protein kinase C {alpha} modulates liver X receptor {alpha} transactivation
J. Endocrinol., April 1, 2008; 197(1): 121 - 130.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Talukdar, S. Bhatnagar, S. Dridi, and F. B. Hillgartner
Chenodeoxycholic acid suppresses the activation of acetyl-coenzyme A carboxylase-{alpha} gene transcription by the liver X receptor agonist T0-901317
J. Lipid Res., December 1, 2007; 48(12): 2647 - 2663.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
M. Nilsson, K. Dahlman-Wright, C. Karelmo, J.-A. Gustafsson, and K. R. Steffensen
Elk1 and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRB gene promoter
Nucleic Acids Res., July 10, 2007; (2007) gkm492v1.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
J. M. Aerts, R. Ottenhoff, A. S. Powlson, A. Grefhorst, M. van Eijk, P. F. Dubbelhuis, J. Aten, F. Kuipers, M. J. Serlie, T. Wennekes, et al.
Pharmacological Inhibition of Glucosylceramide Synthase Enhances Insulin Sensitivity
Diabetes, May 1, 2007; 56(5): 1341 - 1349.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
M. A. M. den Boer, P. J. Voshol, F. Kuipers, J. A. Romijn, and L. M. Havekes
Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1360 - E1364.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Talukdar and F. B. Hillgartner
The mechanism mediating the activation of acetyl-coenzyme A carboxylase-{alpha} gene transcription by the liver X receptor agonist T0-901317
J. Lipid Res., November 1, 2006; 47(11): 2451 - 2461.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
F. Lalloyer, B. Vandewalle, F. Percevault, G. Torpier, J. Kerr-Conte, M. Oosterveer, R. Paumelle, J.-C. Fruchart, F. Kuipers, F. Pattou, et al.
Peroxisome Proliferator-Activated Receptor {alpha} Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets
Diabetes, June 1, 2006; 55(6): 1605 - 1613.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.